Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole

Cancer

Volumn 118, Issue 5, 2012, Pages 1192-1201

  Brufsky, Adam M ^a   Harker, W Graydon ^b   Beck, J Thaddeus ^c   Bosserman, Linda ^d   Vogel, Charles ^e   Seidler, Christopher ^f   Jin, Lixian ^g   Warsi, Ghulam ^g   Argonza Aviles, Eliza ^g   Hohneker, John ^g   Ericson, Solveig G ^g   Perez, Edith A ^h  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Utah Cancer Specialists   (United States)

^c Highlands Oncology Group   (United States)

^d Wilshire Oncology Medical Group Inc   (United States)

^e Cancer Research Network Inc   (United States)

^f Fallon Clinic   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h MAYO CLINIC   (United States)

Author keywords

aromatase inhibitors; bone resorption; breast neoplasm; postmenopause; zoledronic acid

Indexed keywords

HORMONE RECEPTOR; LETROZOLE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADULT; AGED; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FRACTURE; HIP; HOT FLUSH; HUMAN; HYPERTENSION; INCIDENCE; INSOMNIA; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; OPEN STUDY; PERIPHERAL EDEMA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MIDDLE AGED; NITRILES; ORGAN SIZE; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; TRIAZOLES;

EID: 84857370664     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26313     Document Type: Review

References (35)

1. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008; 26: 1051-1058.
2. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007; 25: 829-836. (Pubitemid 350002883)
3. Brufsky A, Bundred N, Coleman R, et al. for the Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008; 13: 503-514. (Pubitemid 351872868)
4. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology Breast Cancer (V. 2.2010). Available at:. Accessed on April 14, 2010.
5. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007; 25: 486-492. (Pubitemid 350002953)
6. Thurlimann B, Keshaviah A, Coates AS, et al for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 2747-2757. (Pubitemid 43016814)
7. Howell A, Cuzick J, Baum M, et al for the ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60-62.
8. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369: 559-570.
9. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of the BSCSG trial 8 and ARNO 95 trial. Lancet. 2005; 366: 455-462. (Pubitemid 41111693)
10. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M,. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008; 9: 45-53.
11. Mouridsen H, Giobbie-Hurder MS, Goldhirsch A, et al for the BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009; 361: 766-776.
12. Zometa, A. Package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
13. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008; 112: 1001-1010. (Pubitemid 351304583)
14. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009; 9: 77-85.
15. Hines SL, Mincey B, Dentchev T, et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009; 117: 603-609.
16. Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: Bone health in cancer care. J Natl Compr Canc Netw. 2009; 7 (suppl 3): S1-S36.
17. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al for the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008; 9: 840-849.
18. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open-label, randomized, phase 2 trial. Lancet Oncol. 2010; 11: 421-428.
19. Lin AY, Park JW, Scott M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J Clin Oncol. 2008; 26 (suppl 15S): 20s. Abstract 559.
20. Solomayer E, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, Tex. Abstract 2048.
21. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumor activity in breast cancer. Br J Cancer. 2010; 102: 1099-1105.
22. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M,. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010; 15: 382-389.
23. Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Tex. Abstract 511.
24. Ottewell PD, Lefley DV, Cross SS, et al. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in breast cancer model. Int J Cancer. 2010; 126: 522-532.
25. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I,. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008; 100: 1167-1178.
26. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001; 84: 1126-1134. (Pubitemid 32448513)
27. Lu S, Zhang J, Zhou Z, et al. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastases in nude mice. Oncol Rep. 2008; 20: 582-587.
28. Gnant M, Mlineritsch B, Schippinger W, et al for the ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360: 679-691.
29. Aviles A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007; 24: 227-230. (Pubitemid 350135975)
30. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 2009; 125: 1705-1709.
31. Rennert G, Pinchev M, Rennert HS,. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010; 28: 3577-3581.
32. Chelbowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010; 28: 3582-3590.
33. Bonnick SL, Johnston CC Jr, Kleerekoper M, et al. Importance of precision in bone density measurements. J Clin Densitom. 2001; 4: 105-110. (Pubitemid 32643312)
34. Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, Tex. Abstract S4-5.
35. Chustecka Z,. AZURE: Zoledronic acid effect on breast cancer is complicated. Available at:. Accessed April 5, 2011.